We are the combination of four hospitals: the General Hospital, the Children’s Hospital, the Women’s Hospital and the Traumatology, Rehabilitation and Burns Hospital. We are part of the Vall d’Hebron Barcelona Hospital Campus: a world-leading health park where healthcare plays a crucial role.
Patients are the centre and the core of our system. We are professionals committed to quality care and our organizational structure breaks down the traditional boundaries between departments and professional groups, with an exclusive model of knowledge areas.
Would you like to know what your stay at Vall d'Hebron will be like? Here you will find all the information.
The commitment of Vall d'Hebron University Hospital to innovation allows us to be at the forefront of medicine, providing first class care adapted to the changing needs of each patient.
Members of the RBDCOV project.
RBDCOV aims to test the HIPRA vaccine against COVID-19 in children (including adolescents) and immunocompromised people.
On 10 October, Vall d'Hebron hosted the third annual meeting of the RBDCOV project ("RBD Dimer recombinant protein vaccine against SARS-CoV-2"). The aim of this initiative, in which the Infection and Immunity in Paediatric Patients group of Vall d'Hebron Research Institute (VHIR) participates, is to test the efficacy, tolerability and safety of HIPRA's COVID-19 vaccine (BIMERVAX®) in children and adolescents, and also in immunocompromised individuals. The project is part of the Horizon Europe programme.
The meeting was the opportunity to establish the next steps in the research of the HIPRA vaccine. In parallel, the provisional results of the study in immunocompromised adults were presented, confirming the safety and efficacy of the vaccine in this population, as well as the durability of protection even against the viral variants currently circulating in the majority of cases. Regarding the study in paediatric and adolescent patients, recruitment data were presented, showing a progressive increase in the number of participants in the five participating centres.
"It is especially important to have efficacy and safety data on BIMERVAX® in the paediatric and adolescent population, so all those involved in this study are making an effort to increase the recruitment of participants in order to reach the 300 individuals needed to evaluate the results", says Dr. Pere Soler Palacín, head of the Infectious Pathology and Immunodeficiency Unit of Paediatrics at Vall d'Hebron University Hospital and of the Infection and Immunity in Paediatric Patients group at VHIR.
RBDCOV Project
RBDCOV is one of the projects committed to testing and advancing the new vaccine against COVID-19. To this end, companies and institutions from five European countries are joining forces to make collaborative progress. The project is led by the biotech pharmaceutical company HIPRA and involves the participation of centres in Spain (Vall d'Hebron Research Institute, Irsicaixa, Fundación Lucha contra el SIDA (FLS), IDIBAPS, IDIBGI, ASPHALION, Vinces Consulting, Zabala Innovation), United Kingdom (Veristat International), Italy (Fondazione Penta), Germany (European AIDS Treatment Group), and Turkey (Metpharm Arastirma Gelistirme Saglik Danismanlik). Specifically, Vall d'Hebron is leading the study in children and adolescents.
The recruitment is currently open for adolescents between 12 and 18 years of age who wish to participate in the clinical trial. Parents or tutors of minors interested in participating can contact the people in charge of the study by email or telephone:
The acceptance of these terms implies that you give your consent to the processing of your personal data for the provision of the services you request through this portal and, if applicable, to carry out the necessary procedures with the administrations or public entities involved in the processing. You may exercise the mentioned rights by writing to web@vallhebron.cat, clearly indicating in the subject line “Exercise of LOPD rights”. Responsible entity: Vall d’Hebron University Hospital (Catalan Institute of Health). Purpose: Subscription to the Vall d’Hebron Barcelona Hospital Campus newsletter, where you will receive news, activities, and relevant information. Legal basis: Consent of the data subject. Data sharing: If applicable, with VHIR. No other data transfers are foreseen. No international transfer of personal data is foreseen. Rights: Access, rectification, deletion, and data portability, as well as restriction and objection to its processing. The user may revoke their consent at any time. Source: The data subject. Additional information: Additional information can be found at https://hospital.vallhebron.com/es/politica-de-proteccion-de-datos.